✦ LIBER ✦

Endometrial safety of continuous combined hormone replacement therapy with 17β-oestradiol (1 or 2 mg) and dydrogesterone

✍ Scribed by C. Bergeron; A. Ferenczy

Book ID: 117531428
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 108 KB
Volume: 37
Category: Article
ISSN: 0378-5122
DOI: 10.1016/s0378-5122(00)00176-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Continuous combined hormone replacement

Continuous combined hormone replacement therapy with 1 mg 17β-oestradiol and 5 mg dydrogesterone (Femoston®-conti): Endometrial safety and bleeding profile

✍ C. Quereux; B. Pornel; C. Bergeron; A. Ferenczy 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 101 KB

Ultra low dose continuous combined hormo

Ultra low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone: Protection of the endometrium and amenorrhoea rate

✍ C. Bergeron; F.F. Nogales; T. Rechberger; T. Tatarchjuk; L. Zipfel 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 279 KB

Clinical profile of a new hormone replac

Clinical profile of a new hormone replacement therapy containing 2 mg 17β-estradiol and 10 mg dydrogesterone

✍ Michael O Sator; Fritz Nagele; Paul Sator; Sanja Travica; Doris Gruber; Johannes 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 115 KB

F138 Prevention of postmenopausal bone l

F138 Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy (HRT) with 17-β oestradiol (E2) and dydrogesterone

✍ K Lippuner; W Hänggi; MH Birkhäuser; Ph Jaeger 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 171 KB

Oral ultra-low dose continuous combined

Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study

✍ John C. Stevenson; Gemma Durand; Elke Kahler; Tomasz Pertyński 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 383 KB

Prevention of Postmenopausal Bone Loss U

Prevention of Postmenopausal Bone Loss Using Tibolone or Conventional Peroral or Transdermal Hormone Replacement Therapy with 17β-Estradiol and Dydrogesterone

✍ Kurt Lippuner; Willy Haenggi; Martin H. Birkhaeuser; Jean-Paul Casez; Philippe J 📂 Article 📅 1997 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 351 KB